StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
81
Period ended Jun 30, 2026
Change on a year earlier
+26.6%
64 in Q2 2025
History
33 quarters
Since Q2 2018
Sources
32
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202681+26.6%Form 10-Q (amgn-20260630.htm, filed 2026-08-05) ↗
Q1 2026Mar 31, 202668-20.0%Form 10-Q (amgn-20260331.htm, filed 2026-05-01) ↗
Q4 2025Dec 31, 202572-16.3%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Q3 2025Sep 30, 202590+16.9%Form 10-Q (amgn-20250930.htm, filed 2025-11-05) ↗
Q2 2025Jun 30, 202564-20.0%Form 10-Q (amgn-20250630.htm, filed 2025-08-06) ↗
Q1 2025Mar 31, 202585+30.8%Form 10-Q (amgn-20250331.htm, filed 2025-05-02) ↗
Q4 2024Dec 31, 202486+17.8%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Q3 2024Sep 30, 202477-12.5%Form 10-Q (amgn-20240930.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202480+2.6%Form 10-Q (amgn-20240630.htm, filed 2024-08-07) ↗
Q1 2024Mar 31, 202465+1.6%Form 10-Q (amgn-20240331.htm, filed 2024-05-03) ↗
Q4 2023Dec 31, 202373-33.0%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202388-14.6%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202378-11.4%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202364-34.7%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022109+23.9%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022103+33.8%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Cite this data

StockData. (2026). Amgen Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M) ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_aimovig_us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.